Assurance of tissue oxygen delivery that matches oxygen demand is the most important yet difficult-toaccomplish goal during the complex process of transition from in-utero to ex-utero life, especially in the very preterm neonate. Our inability to continuously monitor the essential parameters of cardiovascular function such as blood pressure, systemic and organ blood flow and cerebral blood flow autoregulation and flowmetabolism coupling in absolute numbers has led to uncertainty in distinguishing normal from abnormal hemodynamic adaptation. This in turn has resulted in treatment of patients that do not require intervention and observation of those that might benefit form appropriate interventions. In addition, we do not know which patient would benefit from which treatment i.e. from administration of volume or vasopressors, inotropes or lusitropes. Importantly, as we have not been able to characterize the physiology of hemodynamic transition, our interventional trials have been based on unclear and sometimes misguided hypotheses. No wonder there is very little evidence that treatment of neonatal cardiovascular compromise in the transitional period results in improved survival and long-term neurodevelopmental outcomes.
